New Jersey Biotech Nets $50M+ BARDA Contract for Respiratory Candidate

Ea­gle Phar­ma­ceu­ti­cals is keep­ing an eye on Enalare Ther­a­peu­tics’ lead res­pi­ra­to­ry can­di­date, and ap­par­ent­ly, so is the US gov­ern­ment.

The New Jer­sey-based biotech struck a deal with BAR­DA worth up to $50.3 mil­lion to de­vel­op the lead com­pound, dubbed ENA-001, the com­pa­ny an­nounced on Tues­day. The can­di­date is de­signed to sim­u­late breath­ing and is meant to be used in emer­gency cas­es when treat­ing drug over­dos­es or res­pi­ra­to­ry de­pres­sion post-surgery.

Ac­cord­ing to Enalare, the first phase of the con­tract will give it $6 mil­lion to com­plete any ac­tions through its Phase I tri­al. The over­all award, which will be based on sev­er­al mile­stones in R&D and pro­duc­tion, will give fund­ing for tox­i­col­o­gy, hu­man tri­als, man­u­fac­tur­ing and reg­u­la­to­ry fil­ings.

Read the full article at: endpts.com

• About the Author
• Latest Posts

BioBuzz Media

BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.

• Unlocking Global Health and Wellness with Innovative Hydration Technology: Can AmiLyfe’s Breakthrough Be Better Than Water?
• In Conversation w/ Sharon Willis, Co-Founder, VP Sales & Customer Relations, Integral Molecular
• In Conversation w/ Matthew Gardner, Head of Life Sciences, Americas, CBRE @ Philly Builds Bio+